Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Phase 3 Terminated 456 enrolled Mural Oncology, Inc Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Timeline

Start: 2022-01-10
Primary completion: 2025-01-08
Completion: 2025-05-08

Publications

Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. Future Oncol. 2023 Jul;19(23):1577-1591. doi: 10.2217/fon-2023-0246. Epub 2023 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Doxorubicin	Other / unclassified	40 mg/m2	Intravenous
Comparator	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Nemvaleukin Alfa	Protein / enzyme biologic	6 ug/kg	Intravenous
Comparator	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Comparator	Topotecan	Small molecule	1.25 mg/m2	Intravenous
Comparator	Topotecan	Small molecule	4 mg/m2	Intravenous

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Summary

Timeline

Publications

Drugs

Indications